WHO Archives

06/10/2026

Artificial intelligence brings tremendous potential to pharmaceutical operations, but it also introduces compliance risks that traditional validation approaches were not designed to address. When AI systems are used in GxP environments, the risks to data integrity, product quality, and patient safety must be identified, assessed, and controlled. This blog examines the key compliance risks that AI application validation audits must address and explains how GxP Cellators helps pharmaceutical companies manage these risks.

Risk 1: Non Deterministic Behavior

Traditional computer systems produce the same output for the same input every time. AI systems do not. Machine learning models can produce different outputs for the same input depending on training data, model updates, or contextual factors. This non deterministic behavior creates significant validation challenges.

Audit Considerations:

How do you validate a system that may produce different outputs
How do you define acceptance criteria for non deterministic systems
How do you monitor ongoing performance
How do you detect when model behavior changes

Risk 2: Data Integrity in Training and Operation

AI models depend on data. The quality of training data directly affects model performance. Data integrity issues in training data can lead to biased, inaccurate, or unreliable outputs. Data integrity issues during operation can corrupt model inputs and lead to incorrect outputs.

Audit Considerations:

Is training data sourced from reliable sources
Is training data representative of the intended use population
Are data preprocessing steps documented and controlled
Are audit trails enabled for model inputs and outputs
Are access controls in place to prevent unauthorized changes

Risk 3: Model Governance and Change Control

AI models can be updated frequently. Some systems learn continuously from new data. Traditional change control processes may not be sufficient to manage AI model changes.

Audit Considerations:

Is there a defined process for reviewing and approving model updates
Are model changes subject to change control
Is there a process for revalidating models after updates
Is model version history documented
Is there a process for rolling back problematic updates

Risk 4: Lack of Transparency and Explainability

Many AI models, particularly deep learning models, are black boxes. Understanding why a model produced a specific output can be difficult or impossible. This lack of transparency creates challenges for validation, auditing, and regulatory acceptance.

Audit Considerations:

Is the model architecture documented
Are model assumptions and limitations documented
Is there a process for explaining model outputs
Are human reviewers able to understand and challenge AI outputs
Is there documentation of model development and validation

Risk 5: Human Oversight and Accountability

AI in GxP environments should augment human decision making, not replace it entirely. Without appropriate human oversight, AI errors can go undetected and uncorrected.

Audit Considerations:

Is there a defined process for human review of AI outputs
Are humans able to override or reject AI recommendations
Is there documentation of human interventions
Are personnel trained on the limitations of AI systems
Are decisions made based on AI outputs documented and justified

Risk 6: Vendor and Supplier Management

Many AI applications are provided by external vendors. Vendor management introduces risks related to transparency, quality, and continuity.

Audit Considerations:

Has the AI vendor been qualified
Is there a quality agreement with the AI vendor
Does the vendor provide documentation sufficient for validation
Does the vendor notify you of model updates
Is there a process for auditing the AI vendor
Is there a contingency plan if the vendor discontinues the service

Risk 7: Regulatory Uncertainty

Regulations for AI in GxP are still evolving. Regulatory expectations may change over time. Organizations must monitor regulatory developments and adapt their validation and audit approaches accordingly.

Audit Considerations:

Are regulatory expectations for AI in GxP being monitored
Is there a process for updating compliance as regulations evolve
Is the AI system compliant with current 21 CFR Part 11 requirements
Is the AI system compliant with current EU GMP Annex 11 requirements
Are data integrity requirements being met

How GxP Cellators Helps Manage AI Compliance Risks

GxP Cellators provides specialized AI auditing services that help pharmaceutical companies identify, assess, and mitigate AI compliance risks. Our auditors understand both the regulatory requirements and the technical characteristics of AI systems.

Our AI Risk Management Services Include:

AI compliance risk assessments
AI governance framework audits
Training data quality and integrity audits
AI model validation documentation reviews
Human oversight process audits
AI vendor and supplier audits
Regulatory compliance reviews
Mock AI audits to prepare for inspections

Why Choose GxP Cellators for AI Risk Management:

Auditors with deep experience in GxP and AI technologies
Coverage of FDA, EMA, Health Canada, MHRA, and WHO requirements
Risk based approach tailored to your AI applications
Practical recommendations for risk mitigation
Full confidentiality for your proprietary systems

Frequently Asked Questions

Q1: What are the biggest compliance risks for AI in pharma?

The biggest risks include non deterministic behavior, data integrity issues in training and operation, inadequate model governance, lack of transparency, insufficient human oversight, vendor management gaps, and regulatory uncertainty.

Q2: How can AI compliance risks be mitigated?

Risks can be mitigated through a structured AI governance framework, rigorous training data quality controls, comprehensive model documentation, defined human oversight processes, vendor qualification and auditing, and ongoing regulatory monitoring.

Q3: What role does data integrity play in AI compliance?

Data integrity is fundamental to AI compliance. Training data must be accurate, complete, and representative. Operational data must be protected from unauthorized changes. Audit trails must be enabled for model inputs and outputs.

Q4: How does GxP Cellators help with AI compliance risk management?

GxP Cellators provides AI compliance risk assessments, governance framework audits, training data quality audits, model validation reviews, human oversight audits, and vendor audits. We help you identify and mitigate AI compliance risks.

Q5: How do I contact GxP Cellators for AI risk management support?

You can reach us through our contact page at /contact/ to discuss your AI compliance risk management requirements.

Contact GxP Cellators

If you need support with AI application validation audits and compliance risk management, please contact GxP Cellators.

Contact: /contact/

by Vinod

06/10/2026

Auditing an AI application under GxP requirements requires a different mindset than auditing a traditional computerized system. The auditor must understand not only the regulatory expectations but also the technical characteristics that make AI systems unique. This blog provides a practical guide to planning, executing, and reporting AI application audits in GxP environments. It also explains how GxP Cellators can support your organization through every phase of the audit process.

Phase 1: Audit Planning and Preparation

Understanding the AI Application

Before the audit begins, the auditor must understand the AI application being audited.

What is the intended use of the AI application
What GxP activities does it support
What is the risk level of the application
What type of AI or machine learning model is used
How was the model developed and trained
How does the model produce outputs
What human oversight exists

Reviewing Documentation

The auditor should review available documentation before the audit.

System requirements specification
Validation plan and report
Model development documentation
Training data documentation
Risk assessment
Standard operating procedures
User manuals and training materials

Defining Audit Scope and Criteria

The audit scope should clearly define what will be examined and against what criteria.

Which AI systems or models will be audited
Which GxP regulations and standards apply
What processes and documentation will be reviewed
What personnel will be interviewed
What testing or verification will be performed

Phase 2: Audit Execution

Opening Meeting

The audit begins with an opening meeting to confirm scope, objectives, and logistics.

Introduce the audit team
Confirm the audit scope and criteria
Explain the audit process and timeline
Confirm confidentiality arrangements
Schedule interviews and document reviews

Document Review

The auditor reviews documentation to verify compliance.

Is the validation documentation complete and approved
Is the risk assessment documented and appropriate
Is the training data documentation sufficient
Is the model development documentation complete
Are standard operating procedures current and followed

Interviews

Interviews with key personnel provide insight into actual practices.

System owners and administrators
Quality assurance personnel
End users of the AI application
IT and data management personnel
Vendor representatives if applicable

System Walkthrough

The auditor examines the AI system in operation.

How is the system accessed and used
What controls are in place for data input
How are outputs generated and reviewed
What audit trails exist
How are model updates managed

Testing and Verification

The auditor may perform testing to verify controls.

Verify that audit trails capture required information
Verify that access controls are effective
Verify that outputs are attributable to the system
Verify that human oversight is documented
Verify that model version control is effective

Phase 3: Findings and Classification

Identifying Findings

Findings are identified when practices or documentation do not meet audit criteria.

Critical findings: direct impact on patient safety or data integrity
Major findings: significant deviation from requirements
Minor findings: isolated or low impact issues
Observations: opportunities for improvement

Classifying Findings

Each finding should be classified based on risk and impact.

Classification	Definition	Response Required
Critical	Direct impact on patient safety or data integrity	Immediate action required
Major	Significant deviation from requirements	Corrective action required
Minor	Isolated or low impact issue	Correction recommended
Observation	Opportunity for improvement	Consideration recommended

Phase 4: Reporting and Follow Up

Audit Report

The audit report documents findings and recommendations.

Executive summary
Audit scope and criteria
Methodology
Findings with classification
Root cause analysis where applicable
Corrective and preventive action recommendations
Attachments and evidence

Close Out Meeting

The close out meeting presents findings to the auditee.

Present findings and classifications
Discuss root causes and corrective actions
Confirm timelines for CAPA
Document agreements and disagreements

CAPA Follow Up

The auditor verifies that corrective and preventive actions are implemented.

Review CAPA plans
Verify implementation
Assess effectiveness
Close findings when appropriate

How GxP Cellators Supports AI Application Audits

GxP Cellators provides comprehensive AI application audit services for GxP organizations. Our auditors have experience with both traditional CSV and emerging AI technologies. We help you navigate the unique challenges of auditing AI systems and demonstrate compliance to regulators.

Our AI Audit Services Include:

Full scope AI application audits from planning through reporting
Pre audit readiness assessments for AI systems
Mock AI audits to prepare your team for regulatory inspection
AI governance framework assessments
Data integrity audits for AI systems
AI model validation documentation reviews
Vendor and supplier audits for AI applications
CAPA verification and follow up audits
Training on AI auditing best practices

Why Choose GxP Cellators for AI Audits:

Auditors with deep experience in both GxP and AI technologies
Coverage of FDA, EMA, Health Canada, MHRA, and WHO requirements
Risk based audit approach tailored to your AI applications
Clear, actionable reports that support remediation
Full confidentiality for your proprietary systems

Frequently Asked Questions

Q1: What is the first step in auditing an AI application under GxP?
The first step is understanding the AI application. You must know its intended use, the GxP activities it supports, the type of model used, how it was developed and trained, and what human oversight exists. This understanding forms the basis for the audit plan.

Q2: How long does an AI application audit take?
The duration depends on the complexity of the AI application, the scope of the audit, and the availability of documentation. A focused audit of a single AI application may take several days. A comprehensive audit of multiple AI systems across an organization may take several weeks.

Q3: What qualifications should an AI auditor have?
An AI auditor should have experience with GxP regulations including 21 CFR Part 11 and EU GMP Annex 11. They should understand computer system validation principles. They should also have knowledge of AI and machine learning technologies, including model development, training data, and performance monitoring.

Q4: What are common findings in AI application audits?
Common findings include incomplete AI system inventories, lack of AI governance frameworks, inadequate training data documentation, insufficient model validation documentation, and inadequate human oversight processes.

Q5: How does GxP Cellators support AI application audits?
GxP Cellators provides full scope AI application audits, pre audit readiness assessments, mock audits, governance reviews, data integrity audits, and vendor audits. We help you identify gaps and prepare for regulatory inspections.

Q6: How do I contact GxP Cellators for AI audit support?
You can reach us through our contact page at /contact/ to discuss your AI audit requirements.

Contact GxP Cellators

If you need support with AI application audits under GxP requirements, please contact GxP Cellators.

Contact: /contact/

by Vinod

06/10/2026

Artificial intelligence is no longer a future concept in pharmaceutical operations. It is here today, embedded in manufacturing analytics, clinical data review, pharmacovigilance signal detection, and quality management systems. With this rapid adoption comes a critical question that every quality leader must answer. How do you validate an AI application in a GxP environment?

Traditional computer system validation was built for deterministic systems. You define requirements, you test against those requirements, and you verify that the system does what it is supposed to do every single time. AI systems do not work that way. They learn. They adapt. Their outputs can change based on new data. This fundamental difference creates unique validation challenges that regulators are still working to address.

This blog provides a comprehensive audit checklist for AI application validation in GxP environments. It covers what auditors should examine, what evidence you need, and how to demonstrate compliance when the technology itself is non deterministic. It also explains how GxP Cellators supports pharmaceutical companies through every phase of the AI validation audit process.

Why AI Validation Is Different from Traditional CSV

Traditional CSV follows a linear lifecycle. User requirements are defined. Design specifications are created. The system is built or configured. Testing verifies that the system meets requirements. The system is released and maintained in a validated state.

AI validation must account for characteristics that traditional CSV does not address.

Non deterministic outputs. An AI model may produce different outputs for the same input depending on training data, model updates, or contextual factors. This means that traditional pass or fail testing may not be sufficient. Validation must include statistical approaches and ongoing monitoring.
Continuous learning. Some AI systems update their models based on new data, which means the validated state can change without a formal change control trigger. Organizations must define what constitutes a significant model change and establish processes for reviewing and approving updates.
Opacity. Many AI models, particularly deep learning models, are black boxes. Understanding why a model produced a specific output can be difficult or impossible. Validation documentation must address model explainability to the extent possible and define human oversight requirements.
Data dependency. AI model performance depends heavily on the quality, completeness, and representativeness of training data. Validation must include assessment of training data quality and governance.
Evolving performance. Model performance can degrade over time as real world conditions diverge from training conditions. Ongoing performance monitoring is essential for maintaining the validated state.

The GxP AI Validation Audit Checklist

Section 1: AI System Inventory and Risk Assessment

Before validating any AI application, you must know what AI systems you have and how much risk each one carries. A complete inventory is the foundation of any validation program.

Have you identified all AI and machine learning applications used in GxP activities
Is each AI application documented in your system inventory
Has each AI application been risk assessed for its impact on product quality and patient safety
Is the risk assessment documented and approved
Has the risk assessment considered the specific characteristics of AI systems
Are high risk AI applications subject to more stringent validation requirements
Is the inventory reviewed and updated on a regular basis
Are new AI applications added to the inventory before deployment

Section 2: AI Governance and Oversight

AI governance ensures that AI systems are developed, deployed, and maintained responsibly. Without governance, AI systems can proliferate without appropriate oversight.

Is there a documented AI governance framework
Are roles and responsibilities for AI systems clearly defined
Is there an AI oversight committee or equivalent governance body
Are AI systems subject to the same change control processes as other GxP systems
Is there a process for reviewing and approving AI model updates
Are AI related risks included in the quality risk management system
Is there a process for retiring or decommissioning AI systems
Are governance decisions documented and communicated

Section 3: Training Data Quality and Governance

AI model performance depends on the data used to train and validate it. Poor quality training data leads to poor quality outputs.

Is training data sourced from reliable and qualified sources
Is training data representative of the intended use population
Has training data been assessed for completeness and accuracy
Is there documentation of data preprocessing and feature engineering
Has training data been reviewed for bias and fairness
Is there a process for managing training data updates
Are data provenance and lineage documented
Is training data protected from unauthorized modification

Section 4: AI Model Development and Validation

The model itself must be developed and validated using a documented, risk based approach.

Is there a documented model development methodology
Are model requirements defined and traceable
Has the model been validated against predefined acceptance criteria
Are performance metrics appropriate for the intended use
Has the model been tested with independent validation data
Is there documentation of model limitations and assumptions
Has the model been reviewed and approved by qualified personnel
Is there a process for ongoing model performance monitoring

Section 5: AI Model Documentation

Documentation is essential for regulatory acceptance and ongoing maintenance.

Is the intended use of the AI application clearly documented
Is the model architecture documented
Are model inputs and outputs clearly defined
Are model assumptions and limitations documented
Is the training data documented
Are validation results documented
Is there documentation of model version history
Is there a process for updating documentation when models change

Section 6: Human Oversight and Intervention

AI in GxP environments should augment human decision making, not replace it entirely. Human oversight ensures that AI errors are detected and corrected.

Is there a defined process for human review of AI outputs
Are humans able to override or reject AI recommendations
Is there documentation of human interventions
Are personnel trained on the limitations of AI systems
Is there a process for escalating AI related concerns
Are decisions made based on AI outputs documented and justified
Is there a process for monitoring the effectiveness of human oversight

Section 7: Data Integrity for AI Systems

Data integrity principles apply to AI systems just as they do to any GxP system.

Are audit trails enabled for AI system inputs and outputs
Are access controls in place to prevent unauthorized changes
Are AI model changes documented and approved
Is there a process for detecting and investigating data integrity issues
Are AI outputs attributable to the system and any human reviewers
Is data associated with AI systems legible, contemporaneous, original, and accurate
Are data backups performed and tested
Is data protected from loss or corruption

Section 8: AI System Security

AI systems can be vulnerable to unique security threats.

Is the AI system protected from unauthorized access
Is there protection against adversarial inputs
Is there protection against data poisoning
Is there protection against model theft
Are security incidents documented and investigated
Is there a process for responding to AI specific security incidents
Are security controls tested and updated regularly

Section 9: Regulatory Compliance

AI systems in GxP must comply with applicable regulations.

Does the AI system comply with 21 CFR Part 11 for electronic records and signatures
Does the AI system comply with EU GMP Annex 11 for computerized systems
Is the AI system compliant with data integrity requirements
Are regulatory expectations for AI in GxP being monitored
Is there a process for updating compliance as regulations evolve
Are regulatory submissions involving AI systems supported by appropriate documentation

Section 10: Vendor and Supplier Management

Many AI applications are provided by external vendors.

Has the AI vendor been qualified
Is there a quality agreement with the AI vendor
Does the vendor provide documentation sufficient for validation
Does the vendor notify you of model updates
Is there a process for auditing the AI vendor
Is there a contingency plan if the vendor discontinues the service
Are vendor performance and compliance monitored on an ongoing basis

How GxP Cellators Supports AI Application Validation Audits

GxP Cellators provides specialized AI application validation audits for pharmaceutical, biotechnology, and medical device companies. Our auditors understand both the regulatory requirements and the technical characteristics of AI systems. We help you build confidence in your AI applications and demonstrate compliance to regulators.

Our AI Validation Audit Services Include:

AI system inventory and risk assessment reviews
AI governance framework assessments
Training data quality audits
AI model validation documentation reviews
Human oversight process audits
Data integrity audits for AI systems
AI security assessments
Regulatory compliance reviews for 21 CFR Part 11 and Annex 11
Vendor and supplier audits for AI applications
CSV AI support for emerging technologies
Mock AI audits to prepare for regulatory inspection
CAPA verification and follow up audits

Why Choose GxP Cellators for AI Validation Audits:

Auditors with both CSV and AI technology experience
Coverage of FDA, EMA, Health Canada, MHRA, and WHO requirements
Risk based approach tailored to your AI applications
Practical, actionable reports that support remediation
Full confidentiality for your proprietary AI systems
Global reach with regional expertise

Conclusion

AI application validation is one of the most complex challenges facing GxP organizations today. The technology is evolving faster than the regulations, and auditors must navigate uncertainty while maintaining compliance. A structured, risk based approach to AI validation auditing helps you identify gaps, address risks, and demonstrate that your AI systems are fit for purpose.

Frequently Asked Questions

Q1: What is AI application validation in GxP?
AI application validation in GxP is the process of demonstrating that an artificial intelligence system used in regulated activities is fit for its intended purpose. It includes documenting the intended use, validating model performance, ensuring data integrity, establishing human oversight, and maintaining the validated state over time.

Q2: How is AI validation different from traditional CSV?
AI validation differs from traditional CSV in several ways. AI systems may be non deterministic, meaning the same input can produce different outputs. They may learn continuously from new data. They are often less transparent than traditional systems. And their performance can degrade over time. These characteristics require validation approaches that go beyond traditional requirements based testing.

Q3: What regulations apply to AI applications in GxP?
The primary regulations are 21 CFR Part 11 for electronic records and signatures, EU GMP Annex 11 for computerized systems, and data integrity requirements based on ALCOA+ principles. GAMP 5 provides a risk based framework for validation. Regulatory guidance for AI in GxP is still evolving.

Q4: How often should AI applications be revalidated?
Revalidation triggers should be defined based on risk. Triggers may include significant model updates, changes in training data, changes in intended use, performance degradation, or regulatory changes. Ongoing performance monitoring helps identify when revalidation is needed.

Q5: What documentation is required for AI validation?
Required documentation includes system requirements, model development methodology, training data documentation, validation plan and report, risk assessment, standard operating procedures, human oversight procedures, and change control records.

Q6: How does GxP Cellators help with AI validation audits?
GxP Cellators provides comprehensive AI validation audit services including pre audit assessments, governance reviews, training data audits, model validation documentation reviews, data integrity audits, and mock inspections. We help you identify gaps and prepare for regulatory scrutiny.

Q7: How do I contact GxP Cellators for AI validation audit support?
You can reach us through our contact page at /contact/ to discuss your AI validation audit requirements.

Contact GxP Cellators

If you need support with AI application validation audits in your GxP environment, please contact GxP Cellators. Our team of experts is ready to help you navigate the unique challenges of AI compliance.

Contact: /contact/

by Vinod

15/08/2026

The Path to Audit Success

A successful GLP audit does not happen by accident. It is the result of careful planning, thorough preparation, and a genuine commitment to GLP principles. Organizations that consistently pass GLP audits with few or no findings invest significant effort in audit preparation.

Preparing for a GLP audit can seem daunting, especially given the breadth of GLP requirements. However, by taking a systematic approach and focusing on the areas that regulators care about most, you can transform audit preparation from a stressful scramble into a manageable process.

This article provides a comprehensive guide to preparing your research laboratory for a successful GLP audit. Whether you are preparing for your first GLP audit or seeking to improve your compliance posture, these strategies will help you achieve audit success.

Understanding What Regulators Look For

Before you can prepare for a GLP audit, you must understand what regulators will be looking for. GLP inspectors evaluate compliance across multiple areas, including:

Organization and Personnel
Regulators verify that your laboratory has qualified personnel with clearly defined responsibilities. They check training records and ensure that Study Directors are properly designated.

Quality Assurance Unit
Regulators evaluate the independence and effectiveness of your QAU. They review QAU inspection records and ensure that the QAU has performed protocol and final report reviews.

Facilities and Equipment
Regulators inspect your facilities to ensure they are adequate and well-maintained. They review equipment calibration and maintenance records.

Test and Reference Items
Regulators verify that test and reference items are properly characterized, stored, and handled.

Standard Operating Procedures
Regulators review your SOPs to ensure they are comprehensive, current, and available to personnel.

Study Performance
Regulators evaluate how studies are conducted, from protocol approval to data recording. They ensure that deviations are documented and justified.

Data Integrity
Regulators scrutinize data for accuracy, completeness, and traceability. They review audit trails for electronic records.

Archives
Regulators inspect archives to ensure that study records and samples are securely stored and accessible.

Phase 1: Pre-Audit Preparation

Pre-audit preparation is the foundation of audit success. This phase involves assessing your current compliance posture, identifying gaps, and taking corrective action.

Conduct a Self-Audit
The first step in pre-audit preparation is to conduct a thorough self-audit. This involves reviewing your GLP systems against regulatory requirements and identifying areas of non-compliance. A self-audit can be conducted by your internal QAU or by external consultants.

Identify Gaps
Based on your self-audit, identify gaps in your GLP systems. These may include missing documentation, inadequate training, or deficient facilities. Prioritize gaps based on their severity and the likelihood of regulatory finding.

Develop a CAPA Plan
For each identified gap, develop a corrective and preventive action plan. The CAPA plan should include specific actions, responsible parties, timelines, and verification procedures.

Implement Corrective Actions
Implement the corrective actions identified in your CAPA plan. This may involve updating SOPs, providing additional training, or repairing equipment.

Verify Effectiveness
Once corrective actions are implemented, verify that they are effective. This may involve additional self-audits or monitoring of key performance indicators.

Phase 2: Audit Preparation Activities

With your compliance gaps addressed, you can move to more specific audit preparation activities.

Organize Your Documentation
Regulators will request documentation during the audit. Organize your documentation in advance to ensure you can provide it quickly. This includes study plans, raw data, final reports, SOPs, training records, and equipment records.

Prepare Your Facilities
Ensure that your facilities are clean, organized, and in good repair. Remove clutter and ensure that work areas are tidy. Check that signage is clear and that safety equipment is visible.

Prepare Your Personnel
Ensure that all personnel are aware that an audit is scheduled and understand their roles during the audit. Provide training on audit procedures, including how to respond to inspector questions.

Conduct Mock Audits
Mock audits are one of the most effective ways to prepare for a GLP audit. During a mock audit, an internal or external auditor conducts a simulated inspection, identifying areas for improvement and providing practice in responding to inspector questions.

Review Previous Audit Findings
If you have undergone previous GLP audits, review the findings and ensure that corrective actions are complete and effective. Regulators expect that previous findings have been addressed.

Phase 3: During the Audit

During the audit, your focus should be on cooperating with the inspector and providing complete and accurate information.

Designate an Audit Host
Designate an individual to serve as the host for the inspector. This person should be knowledgeable about your GLP systems and able to answer questions and facilitate access to personnel and records.

Respond to Inspector Questions Honestly
When the inspector asks questions, respond honestly and accurately. If you do not know the answer, say so and offer to find out. Do not speculate or provide inaccurate information.

Provide Documentation Promptly
When the inspector requests documentation, provide it promptly. If documentation is not immediately available, explain why and provide an estimated time when it will be available.

Take Notes
Take notes during the audit, especially of any observations or concerns expressed by the inspector. This will help you address findings after the audit.

Remain Professional
Throughout the audit, remain professional and courteous. Do not become defensive or argumentative, even if you disagree with the inspector’s observations.

Phase 4: Post-Audit Activities

After the audit, your focus should shift to addressing any findings and preparing for future audits.

Review Audit Findings
When you receive the audit report, review the findings carefully. Identify any areas of non-compliance and determine the root causes.

Develop CAPA Plans
For each finding, develop a CAPA plan. The plan should include specific actions, responsible parties, timelines, and verification procedures.

Implement CAPA Actions
Implement the CAPA actions identified in your plan. This may involve updating SOPs, providing additional training, or making facility improvements.

Verify Effectiveness
Once CAPA actions are implemented, verify that they are effective. This may involve additional self-audits or monitoring of key performance indicators.

Document CAPA Activities
Document all CAPA activities, including the original finding, the corrective action taken, and the verification of effectiveness. This documentation should be retained for future reference.

Learn from the Experience
Reflect on the audit experience and identify lessons learned. Consider how you can improve your compliance systems and audit preparation processes for future audits.

How GxP Cellators Can Help You Prepare for a GLP Audit

At GxP Cellators, we understand the challenges of preparing for a GLP audit. With over 500 GLP audits successfully completed, our certified GLP and IRCA auditors bring extensive experience in helping laboratories achieve audit readiness.

Our team includes professionals with RQAP-GLP and IRCA Auditor certifications, ensuring that our auditing methodologies comply with international standards. We perform GLP audits on behalf of clients and sponsors, providing objective, third-party evaluations that carry greater credibility with regulatory authorities.

Our audit preparation services include:

Gap assessments: Comprehensive reviews of your GLP systems against OECD guidelines and 21 CFR Part 58, identifying compliance gaps and providing actionable recommendations
Mock audits: Simulated inspections that provide practice in responding to inspector questions and identifying areas for improvement
Readiness audits: Comprehensive assessments of your audit readiness, identifying areas that need attention before the actual audit
Documentation review: Thorough reviews of study plans, raw data, final reports, SOPs, training records, and other documentation
CAPA support: Assistance in developing and implementing CAPA plans for identified gaps
Full-spectrum GLP study audits: Including toxicology, pharmacokinetics, bioanalytical method validation, genotoxicity, reproductive toxicology, carcinogenicity, dermal and ocular toxicology, and ecotoxicology

Why sponsors choose us: We speak both the regulatory language and the scientific language. Our findings are factual, evidenced, and actionable. As an independent third-party audit firm, we have no organizational biases or conflicts of interest. Our audit reports carry greater credibility with regulatory authorities, clients, and business partners.

Our global presence spans Saskatchewan, Calgary, Toronto, North Carolina, Indiana, and Frankfurt, enabling us to deploy auditors worldwide and understand local regulatory nuances while upholding the OECD framework.

Ready to prepare your research laboratory for a successful GLP audit? Let GxP Cellators help you achieve GLP readiness with confidence.

Reach out to us today to schedule your GLP audit.

Email:

Phone: +1 (306) 715-9460

Website: /gxp-auditing/

GxP Cellators – Your Certified GLP Audit Partners

by Vinod

15/08/2026

Documentation Is the Heart of GLP Compliance

If there is one area where laboratories consistently fall short during GLP audits, it is documentation. The FDA’s 483 observations and Warning Letters are filled with documentation-related findings, and OECD GLP inspectors similarly cite documentation deficiencies as a major area of non-compliance.

Documentation is the heart of GLP compliance. Regulatory agencies cannot inspect your laboratory operations directly. They must rely on your documentation to understand how studies were conducted, what data was generated, and whether GLP principles were followed.

This article identifies the most common documentation errors found during GLP audits and provides practical guidance on how to avoid them. By understanding these common pitfalls, you can strengthen your documentation practices and reduce your risk of audit findings.

Visit for more info: /gxp-auditing/

Error 1: Corrections That Obscure Original Entries

One of the most serious documentation errors is making corrections that obscure the original entry. This includes using correction fluid or tape, overwriting, or otherwise making the original entry illegible.

Why This Is a Problem
Regulatory agencies expect that all data entries will be permanent and traceable. Obscuring the original entry makes it impossible to determine what was originally recorded, raising questions about whether data was manipulated.

How to Correct This Error
The proper correction procedure is to strike through the original entry with a single line, enter the correction, and date and initial the change. The original entry must remain legible. For electronic records, corrections must be documented through the audit trail.

How to Prevent This Error
Train all personnel on proper correction procedures. Prohibit the use of correction fluid or tape. Ensure that electronic systems have audit trails that document all changes.

Error 2: Missing Signatures and Dates

Auditors frequently find records that lack signatures or dates. This includes raw data sheets, study plans, deviation logs, and final reports.

Why This Is a Problem
Signatures and dates are essential for establishing attributability and contemporaneity. Without signatures, it is impossible to know who generated or reviewed the data. Without dates, it is impossible to know when activities occurred.

How to Correct This Error
Records that lack signatures or dates should be identified and corrected immediately. The individual who generated or reviewed the data should sign and date the record, with an explanation of why the signature was missing.

How to Prevent This Error
Implement procedures that require signatures and dates for all records. Train personnel on the importance of signing and dating records. Use checklists to ensure that all documentation is complete.

Error 3: Data Recorded on Loose Notes

Another common error is recording data on loose notes, scrap paper, or sticky notes before transcribing it to official study records.

Why This Is a Problem
Data should be recorded directly into official study records. Transcription from loose notes increases the risk of errors and omissions. Loose notes can also be lost or destroyed, resulting in data loss.

How to Correct This Error
Discourage the use of loose notes for data recording. If loose notes are used, they should be attached to the official record, with the transcribed data verified against the original notes.

How to Prevent This Error
Provide personnel with official study records for data recording. Train personnel on the importance of recording data directly into official records. Eliminate the use of loose notes for data recording.

Error 4: Failure to Document Deviations

Deviations from the approved study plan must be documented and justified. Failure to document deviations is a common finding in GLP audits.

Why This Is a Problem
Deviations from the study plan can impact the validity of study results. If deviations are not documented and justified, regulators cannot determine whether the study was conducted as planned.

How to Correct This Error
Implement a deviation management system that documents all deviations from the study plan. Deviations should include a description of the deviation, the reason for the deviation, the impact on the study, and the corrective action taken.

How to Prevent This Error
Train personnel on deviation management procedures. Encourage reporting of deviations. Implement procedures for documenting and justifying all deviations.

Error 5: Missing or Outdated SOPs

Standard Operating Procedures are essential for ensuring that activities are performed consistently and in accordance with GLP principles. Missing or outdated SOPs are a common finding in GLP audits.

Why This Is a Problem
Without SOPs, there is no assurance that activities are performed consistently. Outdated SOPs may not reflect current practices, leading to deviations.

How to Correct This Error
Identify missing or outdated SOPs and develop or update them. Ensure that SOPs are available in the laboratory and that personnel are trained on them.

How to Prevent This Error
Implement an SOP management system that includes regular review and revision. Ensure that SOPs are available in the laboratory. Train personnel on SOPs and document the training.

Error 6: Inadequate Archival Procedures

GLP requires that study plans, raw data, final reports, and samples be archived in a secure and organized manner. Inadequate archival procedures are a common finding in GLP audits.

Why This Is a Problem
Inadequate archival procedures can result in data loss, making it impossible to reconstruct the study. They can also make it difficult for inspectors to access records during an audit.

How to Correct This Error
Implement archival procedures that ensure records are stored securely, organized logically, and accessible to inspectors. Archives should have environmental controls to protect records from damage.

How to Prevent This Error
Designate an archivist responsible for archival procedures. Implement procedures for transferring records to the archive. Conduct periodic audits of the archive to ensure compliance.

How GxP Cellators Can Help You Avoid Documentation Errors

At GxP Cellators, we have conducted over 500 GLP audits and have seen every documentation error imaginable. Our certified GLP and IRCA auditors bring extensive experience in identifying documentation gaps and helping laboratories improve their documentation practices.

Our documentation audit services include:

Comprehensive documentation review covering study plans, raw data, final reports, SOPs, deviation logs, training records, and archival procedures
Gap assessments identifying documentation deficiencies and providing actionable recommendations
Sponsor-side audits of CROs with a focus on documentation practices
Full-spectrum GLP study audits including toxicology, pharmacokinetics, bioanalytical method validation, genotoxicity, reproductive toxicology, carcinogenicity, dermal and ocular toxicology, and ecotoxicology
Detailed audit reports with findings linked to specific regulations and prioritized recommendations
CAPA support and verification to ensure documentation issues are effectively addressed

Ready to strengthen your documentation practices? Let GxP Cellators help you achieve GLP compliance with confidence.

Reach out to us today to schedule your GLP audit.

Email:

Phone: +1 (306) 715-9460

Website: /gxp-auditing/

GxP Cellators – Your Certified GLP Audit Partners

by Vinod

15/08/2026

The Foundation of Regulatory Trust

Data integrity is not merely a regulatory checkbox. It is the foundation upon which regulatory trust is built. When you submit non-clinical safety data to the FDA, EMA, or other regulatory authorities, you are making a promise that the data is accurate, complete, and reliable. GLP audits are designed to verify that promise.

In recent years, data integrity has become a major focus of regulatory inspections worldwide. The FDA has issued numerous Warning Letters citing data integrity violations, and the EMA has published guidance emphasizing the importance of data integrity in GLP studies. Organizations that fail to maintain data integrity face serious consequences, including study rejection, regulatory delays, and potential legal action.

This article explores why data integrity plays a major role in GLP audits and provides practical guidance for ensuring your data meets regulatory expectations.

What Is Data Integrity in the GLP Context?

Data integrity refers to the accuracy, completeness, consistency, and reliability of data throughout its lifecycle. In the GLP context, data integrity encompasses all data generated during a non-clinical study, from raw observations to final reports.

Regulatory agencies expect that data will be:

Accurate: Free from errors and reflecting true observations
Complete: Including all data generated during the study, with no omissions
Consistent: Free from contradictions and logical inconsistencies
Reliable: Trustworthy and verifiable through audit trails
Traceable: Allowing reconstruction of the study from raw data to final report

Data integrity is not just about preventing fraud. It is about ensuring that decisions made based on your data are sound and that regulators can have confidence in your submissions.

The ALCOA+ Framework Explained

Regulatory agencies worldwide use the ALCOA+ framework to assess data integrity. ALCOA+ was originally developed by the FDA and has been adopted by the EMA, WHO, and other regulatory bodies as the standard for data integrity assessment.

The ALCOA+ principles are:

Attributable
Every data point must identify who generated it, when it was generated, and on what system. This requires user identification and authentication for electronic systems and signatures for paper records.
Legible
Data must be readable throughout its retention period. This means using permanent ink for paper records and ensuring electronic records remain accessible as technology evolves.
Contemporaneous
Data must be recorded at the time of the activity, not hours or days later. Contemporaneous recording reduces the risk of errors and omissions and provides a more accurate picture of study conduct.
Original
Data must be the first recording or a certified true copy. Original recordings provide the most reliable evidence of study conduct.
Accurate
Data must be accurate, with verified calculations and consistent units. Inaccurate data, even if unintentional, can compromise study validity.
Plus Principles
The ALCOA+ framework adds five additional principles:
Complete: All data must be included, with no omissions.
Consistent: Data must be logically consistent, with no contradictions.
Enduring: Data must be stored in durable media that will survive throughout the retention period.
Available: Data must be accessible for regulatory inspection throughout the retention period.
Traceable: Data must be traceable through all transformations and manipulations.

Common Data Integrity Violations in GLP Audits

Data integrity violations are among the most common findings in GLP audits. Some of the most frequently cited violations include:

Corrections That Obscure Original Entries
Using correction fluid, overwriting, or obscuring original entries is a serious violation. Correct procedures require striking through the error, entering the correction, and dating and initialing the change.

Missing Signatures and Dates
Auditors frequently find records that are not signed or dated. This makes it impossible to determine who generated the data and when, violating the attributability and contemporaneity principles.

Data Recorded on Loose Notes
Data should be recorded directly into official study records. Recording data on loose notes that are later transcribed increases the risk of errors and omissions.

Undocumented Deviations
Deviations from the approved study plan must be documented and justified. Undocumented deviations suggest that the study may not have been conducted as planned.

Inadequate Audit Trails
Electronic systems must maintain audit trails showing who accessed, modified, or deleted data. Inadequate audit trails make it impossible to verify data integrity.

Data Manipulation
The most serious data integrity violation is deliberate data manipulation. This can include altering data to achieve desired results, deleting data that does not support conclusions, or fabricating data entirely.

Electronic Records and Audit Trails

As laboratories increasingly adopt electronic systems, maintaining data integrity for electronic records has become a major focus of GLP audits. The FDA’s 21 CFR Part 11 establishes requirements for electronic records and electronic signatures, and OECD GLP guidance also addresses computerized systems.

Key requirements for electronic records include:

Validation
Computerized systems must be validated to ensure they perform as intended. Validation documentation must demonstrate that the system meets its specified requirements.

Audit Trails
Electronic systems must maintain audit trails showing who accessed the system, what actions were performed, and when those actions occurred. Audit trails must be enabled and cannot be disabled.

Access Controls
Access to electronic systems must be controlled through user identification and authentication. Users must have appropriate privileges based on their roles.

Backup and Recovery
Electronic records must be backed up regularly to prevent data loss. Disaster recovery procedures must be in place and tested.

Archiving
Electronic records must be archived in a format that remains readable throughout the retention period. As technology evolves, data must be migrated to new formats as needed.

How GxP Cellators Ensures Data Integrity in GLP Audits

At GxP Cellators, we understand that data integrity is the cornerstone of GLP compliance. Our auditors are trained to scrutinize data integrity at every level, from raw data generation to final report preparation.

With over 500 GLP audits successfully completed, our certified GLP and IRCA auditors bring extensive experience in identifying data integrity issues. Our team includes professionals with RQAP-GLP and IRCA Auditor certifications, ensuring that our auditing methodologies comply with international standards.

Our data integrity audit approach includes:

Raw data scrutiny: We check for the golden rules of direct, prompt, legible, dated, signed data with changes documented and no obscuring of original entries
Audit trail review: We verify that electronic systems maintain complete audit trails that cannot be disabled
Deviation analysis: We examine deviation logs to ensure all deviations are documented and justified
Data reconciliation: We trace data from raw observations through intermediate calculations to final reports, verifying accuracy and completeness
System validation review: We examine validation documentation for computerized systems
Backup and archive verification: We confirm that backup and archival procedures are in place and functioning

Our services include:

Internal gap assessments covering data integrity across all ten OECD GLP sections and corresponding subparts of 21 CFR Part 58
Sponsor-side audits of CROs with a focus on data integrity
Full-spectrum GLP study audits including toxicology, pharmacokinetics, bioanalytical method validation, genotoxicity, reproductive toxicology, carcinogenicity, dermal and ocular toxicology, and ecotoxicology
Detailed audit reports with findings linked to specific regulations and actionable recommendations
CAPA support and verification to ensure data integrity issues are effectively addressed

Ready to ensure your data integrity meets GLP standards? Let GxP Cellators help you achieve compliance with confidence.

Reach out to us today to schedule your GLP audit.

Email:

Phone: +1 (306) 715-9460

Website: /gxp-auditing/

GxP Cellators – Your Certified GLP Audit Partners

by Vinod

15/08/2026

The Scope of a GLP Audit

A Good Laboratory Practices audit is a comprehensive examination of your laboratory’s compliance with regulatory requirements. Whether conducted by the FDA, OECD member authorities, or your own internal auditors, a GLP audit covers every aspect of your non-clinical study operations.

Understanding the critical areas that auditors will scrutinize is the first step toward successful audit preparation. This article outlines the key areas every laboratory should review before a GLP audit, helping you identify potential compliance gaps and take corrective action before inspectors arrive.

Auditors examine not just your documentation but also your facilities, equipment, personnel qualifications, and quality systems. They look for evidence that GLP principles are embedded in your daily operations, not just documented in policies that are not followed. By reviewing these critical areas thoroughly, you can transform a potentially stressful audit experience into a smooth and successful inspection.

Critical Area 1: Personnel and Training

What Auditors Review

Auditors will examine the qualifications, training, and responsibilities of all personnel involved in GLP studies. This includes Study Directors, Principal Investigators, QA personnel, and technical staff.

Key Compliance Requirements

Documented job descriptions defining GLP responsibilities are essential. Complete training records for all personnel, including initial and ongoing training, must be maintained. There must be clear designation of Study Directors and Principal Investigators. Training on updated SOPs and regulatory changes must be documented and current.

Common Findings

Inadequate training records are frequently cited in FDA 483 observations. Personnel performing tasks without appropriate training is a significant compliance gap. Unclear roles and responsibilities can lead to confusion and errors. QAU personnel involved in study conduct compromises the independence required for effective quality assurance.

Review Checklist

Verify all personnel have current job descriptions. Confirm training records are complete and up-to-date. Ensure Study Directors are properly designated and qualified. Check that QAU operates with genuine independence. Review training matrices for all personnel to confirm coverage.

Critical Area 2: Quality Assurance Unit

What Auditors Review

Auditors will evaluate the independence, effectiveness, and documentation of your QAU activities. The QAU is the cornerstone of GLP compliance, and its shortcomings are a frequent source of regulatory findings.

Key Compliance Requirements

QAU independence from study conduct is non-negotiable. Study-based inspections of all studies must be conducted and documented. Facility-based inspections of laboratory operations must occur regularly. Process-based inspections of critical procedures must be performed. Protocol and final report reviews must be completed and documented. All QAU activities must be thoroughly documented.

Common Findings

QAU personnel participating in studies they inspect is a critical violation. QAU reporting to Study Directors rather than senior management compromises independence. Insufficient QAU resources leading to superficial inspections is a common issue. Missing or inadequate QAU inspection records are frequently cited.

Review Checklist

Confirm QAU independence from study conduct. Verify study-based inspection records for all studies. Review facility-based inspection schedules and reports. Check process-based inspection documentation. Ensure protocol and final report reviews are documented.

Critical Area 3: Facilities and Equipment

What Auditors Review

Your laboratory’s physical infrastructure and equipment form the foundation of GLP compliance. Auditors will examine whether facilities are adequate, equipment is properly maintained, and systems are validated.

Key Compliance Requirements

Separate laboratory space for routine and specialized procedures must be provided. Environmental controls including temperature, humidity, and ventilation must be documented and monitored. Equipment calibration must occur at defined intervals. Maintenance records for all equipment must be complete and accessible. Computerized systems must be validated with audit trails. Controlled access to electronic systems must be maintained.

Common Findings

Inadequate separation of test systems or species is a frequent violation. Missing or incomplete calibration records are commonly cited. Unvalidated computerized systems pose significant data integrity risks. Inadequate environmental monitoring can compromise study validity. Poor equipment maintenance documentation indicates systemic compliance gaps.

Review Checklist

Verify facility layout meets GLP requirements. Check equipment calibration records and certificates. Review maintenance logs for completeness. Confirm computerized systems are validated. Verify environmental monitoring records are complete and current.

Critical Area 4: Documentation and Data Integrity

What Auditors Review

Documentation is at the heart of GLP compliance. Auditors will examine study plans, raw data, final reports, SOPs, and all other documentation to ensure data integrity and traceability.

Key Compliance Requirements

Approved written study plans for all studies must be in place. Raw data must be recorded promptly and legibly. Traceable modifications to data must be documented. Accurate final reports reflecting raw data must be prepared. SOPs for all activities must be current and available. Secure archiving of plans, data, and samples must be maintained.

Common Findings

Corrections that obscure original entries are a major red flag. Missing signatures or dates indicate poor documentation practices. Failure to document deviations compromises study integrity. Data recorded on loose notes before transcription is unacceptable. Inadequate archival procedures risk data loss. Missing or outdated SOPs indicate systemic compliance issues.

Review Checklist

Verify study plans are approved and documented. Check raw data for completeness and legibility. Review data modifications for traceability. Confirm final reports accurately reflect raw data. Ensure all activities have current SOPs. Verify archival procedures are in place and functioning.

How GxP Cellators Can Help You Prepare for a GLP Audit

At GxP Cellators, we have conducted over 500 GLP audits for clients worldwide. Our certified GLP and IRCA auditors bring extensive experience in identifying compliance gaps and helping laboratories achieve GLP readiness. We offer comprehensive pre-audit reviews covering all critical areas, helping you identify and address potential findings before regulators arrive.

Our team includes professionals with RQAP-GLP and IRCA Auditor certifications, ensuring that our auditing methodologies comply with international standards for management systems and technical compliance. We perform GLP audits on behalf of clients and sponsors, ensuring compliance with OECD guidelines and 21 CFR Part 58.

Our services include:

Internal gap assessments covering all ten OECD GLP sections and corresponding subparts of 21 CFR Part 58
Sponsor-side audits of CROs including pre-study qualification, for-cause investigations, and ongoing monitoring
Full-spectrum GLP study audits covering toxicology, pharmacokinetics, bioanalytical method validation, genotoxicity, reproductive toxicology, carcinogenicity, dermal and ocular toxicology, and ecotoxicology
Detailed audit reports with major and minor non-conformities, observations, and CAPA tracking logs
CAPA support and verification to ensure corrective actions are effective

Ready to review your laboratory’s critical areas? Let GxP Cellators help you achieve GLP readiness with confidence.

Reach out to us today to schedule your GLP audit.

Email:

Phone: +1 (306) 715-9460

Website: /gxp-auditing/

GxP Cellators – Your Certified GLP Audit Partners

by Vinod

15/08/2026

The High Cost of GLP Audit Failure

In the world of non-clinical safety testing, regulatory scrutiny is intensifying. The FDA’s Bioresearch Monitoring (BIMO) program conducts routine surveillance inspections of GLP facilities, and OECD member authorities conduct similar inspections under the Mutual Acceptance of Data (MAD) framework. A single significant finding can invalidate years of research, delay product approvals, and expose your organization to regulatory action, including Warning Letters and Form 483 observations.

Yet, many laboratories treat GLP audit preparation as a frantic scramble. Pulling together documents, double-checking records, and hoping inspectors do not look too closely. This reactive approach is not only stressful but also risky. The organizations that consistently pass GLP audits with flying colors share one thing in common. They have built a culture and infrastructure where compliance is a natural state of operations, not a panic-driven exercise.

Building a laboratory that is always ready for a GLP audit requires a systematic approach that touches every facet of your operations. Here is how to achieve that state of readiness.

Why Audit Readiness Must Be a Continuous State

Regulatory inspections under 21 CFR Part 58 and the OECD Principles of GLP can occur with little notice. The FDA conducts both surveillance inspections, which are routine checks of a laboratory’s compliance, and directed inspections, which are targeted investigations of specific studies or issues. In either scenario, your laboratory’s compliance posture is evaluated in real-time.

The consequences of failure are severe. FDA Warning Letters frequently cite violations such as failure of facility management to verify test article concentration and uniformity, inadequate QAU oversight, and failure to maintain proper documentation. These findings can lead to study rejection, regulatory delays, and significant financial losses.

The solution is to build a laboratory that is compliant every day, not just when an audit is announced. This requires embedding GLP principles into your daily operations and fostering a culture where every staff member understands their compliance responsibilities.

Critical Infrastructure for GLP Compliance

Your laboratory’s physical infrastructure and equipment form the foundation of GLP compliance. Regulatory agencies expect certain standards to be met consistently.

Adequate Laboratory Space
21 CFR Part 58.49 requires that testing facilities provide separate laboratory space for routine and specialized procedures, as needed. Failure to maintain proper separation of test systems or species is a common violation that can compromise data integrity and animal welfare. Laboratories must also ensure that areas are organized to prevent cross-contamination and maintain the integrity of studies.

Calibrated and Maintained Equipment
Equipment used to generate GLP data must be calibrated at defined intervals, with maintenance records readily available. Inspectors will scrutinize calibration certificates and traceability to national standards, maintenance logs and service records, and system suitability and performance verification. Equipment that is not properly calibrated can produce inaccurate data, compromising the validity of entire studies.

Validated Computerized Systems
Electronic systems that generate, manipulate, or store GLP data must be validated, with audit trails enabled and access controls in place. A common pitfall is assuming that electronic systems are automatically compliant. They are not. Without validated audit trails, version control, and backup procedures, electronic records can be worse than paper from a data integrity perspective.

The Critical Role of Personnel and Training

Your staff are your greatest asset in maintaining GLP compliance. They are also your greatest vulnerability if not properly trained and supervised. Key requirements include up to date job descriptions defining GLP responsibilities, documented training records for all personnel, clear designation of Study Directors and Principal Investigators for multi-site studies, and continuous training on updated SOPs and regulatory requirements.

The Study Director serves as the single point of control for each study and holds ultimate responsibility for its scientific conduct and GLP data integrity. They ensure the approved study plan is followed, deviations are justified, and raw data are accurately recorded and traceable. Ultimately, they are accountable for the proper conduct of the study and for ensuring that the final report reflects the data generated.

Quality Assurance Unit Independence

The QAU is the sentinel of GLP compliance, but only if it operates with genuine independence from study conduct. QA personnel operate independently from study conduct, including from the Study Director, to verify GLP compliance through scheduled inspections, audits, and report reviews.

Regulatory agencies have identified common QAU violations that laboratories must avoid. These include QAU personnel participating in studies they inspect, QAU reporting to Study Directors rather than senior management, and insufficient QAU resources leading to superficial inspections.

An effective QAU must conduct study-based inspections, facility-based inspections, and process-based inspections to verify compliance at all levels. The QAU must also perform protocol and final report reviews, ensuring that reports accurately reflect the raw data generated during the study.

Documentation: The ALCOA+ Foundation

Data integrity is the bedrock of GLP compliance. Regulatory agencies worldwide use the ALCOA+ framework to assess data trustworthiness. Data must be attributable, meaning every data point must identify who generated it, when, and on what system. Data must be legible throughout its retention period. Data must be recorded at the time of the activity, not hours or days later. Data must be original, representing the first recording or a certified true copy. Data must be accurate with verified calculations and consistent units. Data must also be complete, consistent, enduring, and available, with no deleted data without justification, no contradictions, durable storage, and accessible archives.

Documentation failures are among the most common FDA 483 observations. Common errors include corrections that obscure original entries such as white-out or overwriting, missing signatures or dates, failure to document deviations, and data recorded on loose notes before being transcribed to official records. Every study begins with an approved written plan. All raw data must be recorded promptly and legibly, and any modification must remain traceable to demonstrate ongoing GLP compliance.

How GxP Cellators Can Help You Build an Audit-Ready Laboratory

At GxP Cellators, we understand that building an audit-ready laboratory requires more than just checking boxes. It demands a comprehensive approach to compliance that touches every aspect of your operations. With over 500 GLP audits successfully completed, our certified GLP and IRCA auditors bring global expertise to help you achieve and maintain GLP compliance.

Our team includes certified professionals with RQAP-GLP and IRCA Auditor certifications, ensuring that our auditing methodologies comply with international standards for management systems and technical compliance. We offer end-to-end GLP auditing services for non-clinical GLP studies, ensuring compliance with OECD guidelines and 21 CFR Part 58.

Our services include gap assessments, readiness audits, mock inspections, and full GLP compliance audits. We perform GLP audits on behalf of clients and sponsors, providing objective, third-party evaluations that carry greater credibility with regulatory authorities.

Our track record speaks for itself. With over 500 GLP audits completed, we have helped laboratories across the globe achieve and maintain GLP compliance. Our findings are factual, evidenced, and actionable. We do not close an audit until we see objective evidence that corrective actions work.

Are you ready to build a laboratory that is always prepared for a GLP audit? Partner with GxP Cellators to achieve GLP compliance with confidence.

Reach out to us today to schedule your GLP audit.

Email:

Phone: +1 (306) 715-9460

Website: /gxp-auditing/

GxP Cellators – Your Certified GLP Audit Partners

by Vinod

09/08/2026

Introduction: The Case for Regular GDP Audits

In the fast‑paced world of pharmaceutical distribution, it is easy to view Good Distribution Practices (GDP) audits as a one‑time event—something you do to satisfy a regulatory requirement or a customer request. This perspective is not only short‑sighted but also potentially dangerous. In reality, GDP audits should be a regular, ongoing process that drives continuous improvement and ensures long‑term compliance.

At GxP Cellators, we have performed over 300 GDP audits across the globe. Our certified GDP auditors have seen the difference that regular audits make. In this comprehensive guide, we will explore why regular GDP audits are essential for pharmaceutical distributors and how GxP Cellators can help you build a sustainable compliance programme.

Why GxP Cellators for Your GDP Auditing Needs?

GxP Cellators is a specialized international consultancy delivering expert auditing and regulatory compliance services to the pharmaceutical, biotechnology, medical device, and broader life sciences sectors. Our mission is to ensure your full alignment with global Good Practice (GxP) and ISO quality standards—safeguarding patient safety, product quality, data integrity, supply chain integrity, and regulatory reliability.

We conduct end‑to‑end, risk‑based audits designed to evaluate, strengthen, and optimize your quality and compliance systems across the life sciences value chain. Our GDP auditing services cover pharmaceutical and medical device distribution networks, including wholesalers, third‑party logistics providers (3PLs), cold chain management, storage controls, transportation validation, and traceability systems.

The Benefits of Regular GDP Audits

Regulatory Compliance

Regulatory requirements for GDP are not static; they evolve over time. Regular GDP audits ensure that you stay current with changing regulations. Our audit methodologies align with leading global regulatory authorities and international standards, including EU‑GDP Guidelines, WHO GDP Guidelines, US FDA cGMP, Health Canada GMP Requirements, and ISO 9001.

Risk Identification and Mitigation

Risks in pharmaceutical distribution are not static either. New products, new suppliers, new routes, and new personnel introduce new risks. Regular GDP audits identify these risks before they become compliance failures.

Continuous Improvement

A single GDP audit provides a snapshot of your compliance at a moment in time. Regular audits provide a longitudinal view, allowing you to track trends, measure improvement, and demonstrate a commitment to quality.

Customer Confidence

Pharmaceutical manufacturers are increasingly selective about their distribution partners. They want to work with organisations that can demonstrate a mature quality culture and a proven track record of GDP compliance. A portfolio of clean audit reports from a reputable firm like GxP Cellators can be a powerful credential.

Operational Efficiency

Regular GDP audits often uncover inefficiencies—duplication of effort, outdated procedures, and unnecessary steps. By addressing these issues, you can improve operational efficiency and reduce costs.

Brand Protection

A single GDP compliance failure can damage your brand reputation irreparably. Regular audits help you avoid the scandals, recalls, and regulatory actions that destroy trust.

How Often Should You Conduct GDP Audits?

The frequency of GDP audits depends on several factors:

Regulatory Requirements – Some regulators require annual audits. Others require audits every two or three years.
Customer Requirements – Many pharmaceutical manufacturers require annual audits of their distribution partners.
Risk Profile – High‑risk operations (e.g., cold chain, biologics, international distribution) may require more frequent audits.
Past Performance – Organisations with a history of findings may benefit from more frequent audits.

As a general rule, we recommend annual GDP audits for most pharmaceutical distributors. This frequency allows you to stay ahead of regulatory changes, identify emerging risks, and demonstrate a commitment to continuous improvement.

The GxP Cellators Approach to Regular GDP Audits

Global Reach, Regional Expertise – Our auditors have hands‑on experience across North America, Europe, Asia‑Pacific, Africa, and Latin America.
Risk‑Based, Tailored Audit Programs – We design custom audit frameworks aligned with your operational risk, regulatory exposure, and certification scope.
Integrated GxP & ISO Competence – We have the ability to assess hybrid quality systems operating under both regulatory and ISO‑based structures.
Regulatory Intelligence – We stay current with evolving regulations and best practices.
For Manufacturers – We ensure that your downstream supply chain partners meet your quality standards.
For Logistics Companies – We help you build client trust by verifying that your facilities, vehicles, and procedures comply with global GDP standards.

What a Regular GDP Audit Covers

A comprehensive GDP audit covers:

The Quality System – Risk management protocols, change control system, and CAPA process.
Infrastructure and Validation – Temperature mapping reports, calibration certificates, and facility qualification.
Operational Integrity – Supplier and customer qualification, returns, recalls, and FEFO.
Personnel Competence – Staff training and awareness.

Building a Sustainable Compliance Programme

Regular GDP audits are just one component of a sustainable compliance programme. Other key elements include:

Internal Audits – Conduct regular internal audits to identify issues before external audits.
Management Review – Regularly review quality metrics, audit findings, and customer complaints.
Training Programme – Maintain a robust training programme with initial and refresher training.
Continuous Improvement – Use audit findings to drive continuous improvement.

Conclusion: Make GDP Audits a Regular Priority

Regular GDP audits are not a luxury; they are an essential component of a sustainable compliance programme. They protect patients, preserve product quality, safeguard your business reputation, and demonstrate your commitment to excellence.

Do not wait for a regulatory inspection or a customer complaint to reveal your vulnerabilities. Contact our GDP auditing experts at today to schedule your regular GDP audit. With over 300 audits performed and a team of certified, experienced auditors, GxP Cellators is your trusted partner in pharmaceutical distribution compliance. Visit our GDP auditing services page at GxP Auditing Services to learn more.

by Vinod

09/08/2026

Introduction: Documentation Is the Backbone of GDP Compliance

In the world of pharmaceutical distribution, if it is not documented, it did not happen. This simple principle underpins every Good Distribution Practices (GDP) audit. Documentation is the evidence that your distribution operations are conducted in a controlled, compliant, and quality‑focused manner. Without proper documentation, even the best practices are invisible to an auditor.

At GxP Cellators, we have performed over 300 GDP audits across the globe. Our certified GDP auditors have reviewed thousands of documentation packages, and we have seen firsthand what works and what does not. In this comprehensive guide, we will outline the key documentation every pharmaceutical distributor should maintain for GDP audit success.

Why Documentation Matters in GDP Audits

Documentation serves multiple critical functions in a GDP audit:

Evidence of Compliance – It provides objective evidence that your operations meet GDP requirements.
Traceability – It enables you to track products from receipt to delivery, supporting recalls and investigations.
Continuous Improvement – It allows you to identify trends, analyse root causes, and implement preventive actions.
Regulatory Inspection Readiness – It demonstrates to regulators that you have a mature quality system.

Our End‑to‑End GDP Auditing Services

At GxP Cellators, we conduct end‑to‑end, risk‑based audits designed to evaluate, strengthen, and optimize your quality and compliance systems. Our GDP auditing services cover pharmaceutical and medical device distribution networks, including wholesalers, third‑party logistics providers (3PLs), cold chain management, storage controls, transportation validation, and traceability systems.

Essential Documentation Categories for GDP Audits

Quality Management System Documentation

Your Quality Management System (QMS) is the foundation of your GDP compliance. Key documents include:

Quality Manual – A high‑level document that describes your quality policy, objectives, and the structure of your QMS.
SOPs (Standard Operating Procedures) – Detailed, written instructions for all GDP‑related activities, including receiving, storage, picking, packing, shipping, temperature monitoring, deviation handling, and CAPA.
Quality Policy – A statement of your organisation’s commitment to quality and compliance.
Organisational Chart – A chart showing the structure of your quality and operational teams, including the designated Responsible Person.

Temperature Control Documentation

Temperature control is one of the most scrutinised areas in any GDP audit. Key documents include:

Temperature Mapping Reports – Reports documenting the temperature mapping of your storage areas and transport vehicles.
Calibration Certificates – Certificates for all temperature monitoring devices, demonstrating that they are calibrated at defined intervals.
Temperature Logs – Continuous temperature records for all storage areas and transport vehicles.
Alarm Test Records – Records of alarm tests, including any failures and corrective actions taken.
Contingency Plans – Plans for responding to temperature excursions, equipment failures, and power outages.

Personnel Documentation

Your staff are your most important asset in maintaining GDP compliance. Key documents include:

Training Records – Records of initial and refresher training for all GDP‑relevant personnel.
Competency Assessments – Assessments demonstrating that staff are competent to perform their duties.
Job Descriptions – Descriptions of roles and responsibilities for all GDP‑relevant positions.
Organisational Charts – Charts showing reporting lines and responsibilities.

Supplier and Customer Qualification Documentation

GDP requires that you work only with qualified suppliers and customers. Key documents include:

Supplier Qualification Files – Files for each supplier, including initial qualification, periodic re‑qualification, audit reports, and performance metrics.
Customer Qualification Records – Records demonstrating that customers are authorised to receive pharmaceutical products.
Agreements and Contracts – Written agreements with suppliers and customers that define quality expectations and responsibilities.

Operational Documentation

Your day‑to‑day operations must be documented to demonstrate compliance. Key documents include:

Receiving Records – Records of all incoming shipments, including product identification, quantity, condition, and temperature upon receipt.
Storage Records – Records of product storage locations and conditions.
Picking and Packing Records – Records of order picking and packing activities.
Shipping Records – Records of all outgoing shipments, including product identification, quantity, destination, and temperature during transit.
Deviation Reports – Reports of any deviations from approved procedures or specifications.
CAPA Records – Records of corrective and preventive actions, including root‑cause analysis, action plans, and effectiveness verification.

Transportation Documentation

Transportation is a critical link in the distribution chain. Key documents include:

Shipping Validation Reports – Reports validating that shipping containers maintain product temperatures under worst‑case conditions.
Vehicle Qualification Records – Records demonstrating that transport vehicles are qualified for GDP‑compliant transport.
Driver Training Records – Records of training for drivers on GDP requirements and procedures.
Temperature Records During Transit – Continuous temperature records for all shipments.

Recall and Returns Documentation

GDP requires that you have robust procedures for recalls and returns. Key documents include:

Recall Procedure – A written procedure for conducting recalls, including roles and responsibilities.
Mock Recall Records – Records of mock recall exercises, demonstrating that your recall procedure is effective.
Returns Management Procedure – A written procedure for handling returns, including quarantine, inspection, and disposition.
Returns Records – Records of all returned products, including reason for return, condition, and disposition.

The GxP Cellators Advantage

At GxP Cellators, we understand that documentation can be overwhelming. That is why we offer comprehensive GDP auditing services that include a thorough review of your documentation systems.

Our certified GDP auditors have hands‑on experience across North America, Europe, Asia‑Pacific, Africa, and Latin America. We design risk‑based, tailored audit programs aligned with your operational risk, regulatory exposure, and certification scope.

For Manufacturers – We ensure that your downstream supply chain partners meet your quality standards.

For Logistics Companies – We help you build client trust by verifying that your facilities, vehicles, and procedures comply with global GDP standards.

Conclusion: Get Your Documentation Audit‑Ready

Documentation is the backbone of GDP compliance. By maintaining complete, accurate, and up‑to‑date documentation, you demonstrate to auditors that your distribution operations are controlled, compliant, and quality‑focused.

Do not wait until the last minute to review your documentation. Contact our GDP auditing experts at today to schedule a comprehensive documentation review. With over 300 audits performed and a team of certified, experienced auditors, GxP Cellators is your trusted partner in GDP audit preparation. Visit our GDP auditing services page at GxP Auditing Services to learn more.

Older Posts